2024-SABCS-Takeaways - 10

SURGICAL ONCOLOGY CONTINUED
Research Roundup
 RRM
Read on for key
takeaways about studies
featured in presentations
at the 2024 SABCS®. For
more details, click on
the linked trial names.
Session recordings will
be available on demand
for registered attendees
through March 31, 2025.
The COMET trial (GS2-05, GS2-06)
compared active monitoring with
mammography every six months
to guideline-concordant care of
surgery with or without RT. At two
years, there was no difference in
ipsilateral breast cancer between
the two arms. Patient-reported
outcomes from the trial showed
little difference between active
surveillance and active treatment,
although differences in quality
of life scores suggest a slight
advantage to active surveillance for
some patients.
The INSEMA randomized trial
(GS2-07) supported results from
the SOUND trial, reported in 2023,
that patients who are cN0/iN0
and iT1 or iT2 with planned breastconserving
surgery can
safely omit SLNB. INSEMA
found no significant
difference in estimated
five-year invasive diseasefree
survival with or
without SLNB.
Data from the BRCA
BCY Collaboration
(GS1-08) exploring the
association between riskreducing
surgeries and
survival in young BRCA
mutation carriers with
breast cancer concluded
that both risk-reducing
mastectomy (RRM) and
risk-reducing salpingooophorectomy
(RRSO) are
associated with improved overall
survival, disease-free and breast
cancer-free interval compared
to not receiving these surgical
procedures. The beneficial effect of
RRSO on overall survival was more
pronounced in BRCA1 carriers than
BRCA2 carriers.
See RRM & RRSO above 
Results from the AXSANA/
EUBREAST 3 (PS6-06) study
suggest that patients who
CLICK TO EXPAND
 RRSO
CLICK TO EXPAND
achieve pCR and either no tumor
cells or micrometastases on
SLNB following neoadjuvant can
safely omit ALND. Diagnostic
ALND should be discouraged in
all patients with ypN0(i+) and all
patients with ypN1(mi) on SLNB
who achieve pCR. ALND should
only be considered in select
patients with ypN1(mi) and nonpCR
breast cancer if adjuvant
treatment is likely to be modified
by high nodal burden, e.g. luminal
tumor in BRCA carriers. 
ON ACTIVE SURVEILLANCE VS. GUIDELINE-CONCORDANT CARE
" This (active surveillance) could be part of our toolkit in select cases
and, with longer follow up, potentially be offered to more patients. "
PUNEET SINGH, MD, MS, Assistant Professor of Breast Surgical Oncology, The University of
Texas MD Anderson Cancer Center
10
2024 SABCS®
| Takeaways

https://events.hubilo.com/sabcs2024/session/252213 https://events.hubilo.com/sabcs2024/session/252213 https://events.hubilo.com/sabcs2024/session/252206 https://events.hubilo.com/sabcs2024/session/252206 https://events.hubilo.com/sabcs2024/session/252237 https://events.hubilo.com/sabcs2024/session/252237

2024-SABCS-Takeaways

Table of Contents for the Digital Edition of 2024-SABCS-Takeaways